# Tocilizumab in Chronic Inflammatory CPPD Disease

> **NCT07254637** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 80 (estimated)

## Conditions studied

- Calcium Pyrophosphate Deposition Disease

## Interventions

- **DRUG:** Tocilizumab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07254637
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04
- **Primary completion:** 2026-10
- **Final completion:** 2029-11
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2026-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07254637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07254637, "Tocilizumab in Chronic Inflammatory CPPD Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07254637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*